OBJECTIVETo investigate the effect of metoclopramide on capsule endoscopy (CE) examination.

METHODSTotal 116 patients referred for CE were randomized into two groups with 58 patients in each group. In treatment group patients received 10 mg metoclopramide intramuscular injection after swallowing the capsule and in control group no metoclopramide was administered. The gastric transit time, small bowel transit time, complete endoscopy rate were observed in both groups.

RESULTSThe CE examination was completed in 51 patients of treatment group (87.9%) and 48 of control group (84.2%). Mean gastric transit time was (32.45 ± 29.63) min in treatment group and (45.81 ± 40.01)min in control group, there was significant difference between two groups (P<0.05). Mean small bowel transit time was (252.69 ± 113.29) min in treatment group and (258.75 ± 83.83) min in control group, there was no significant difference between two groups (P>0.05).

CONCLUSIONMetoclopramide may reduces gastric transit time, but not effect small bowel transit time,which suggests that it might increase the likelihood of complete small-bowel examination in patients undergoing capsule endoscopy.

Adult ; Capsule Endoscopy ; Female ; Gastrointestinal Transit ; drug effects ; Humans ; Male ; Metoclopramide ; therapeutic use ; Middle Aged

AIMTo establish a new, reliable vomiting model in minks.

METHODSAdult male minks (Mustela vison) were randomly divided into groups (n = 6). Cisplatin, apomorphine, copper sulfate and X-radiation were used to establish vomiting model. Retching and vomiting were observed after the vomiting models were given anti-vomiting agents. After the behavioral experiment, assay of 5-HT in the ileum was performed by immunohistologic method.

RESULTSCisplatin 7.5 mg.kg-1 i.p., apomorphine 1.6 mg.kg-1 s.c. and copper sulfate 40 mg.kg-1 ig were shown to evoke vomiting. Retching and vomiting were significantly inhibited in ondansetron and metoclopramide pretreated minks (P < 0.05, P < 0.01).

CONCLUSIONAs a new vomiting model, minks may be of great value in studying vomiting mechanism and screening new antiemetic drugs.

Animals ; Antiemetics ; therapeutic use ; Apomorphine ; Cisplatin ; Copper Sulfate ; Disease Models, Animal ; Male ; Metoclopramide ; therapeutic use ; Mink ; Ondansetron ; therapeutic use ; Vomiting ; chemically induced ; drug therapy

Gastroesophageal reflux disease (GERD) is one of the most common problems in gastrointestinal disorders. With the increase in our understanding on the pathophysiology of GERD along with the development of proton pump inhibitors, the diagnostic and therapeutic approaches to GERD have changed dramatically over the past decade. However, GERD still poses a problem to many clinicians since the spectrum of the disease has evolved to encompass more challenging presentations such as refractory GERD and extraesophageal manifestations. This has led to significant confusion regarding the optimal approach to these patients. This article aims to discuss current issues on GERD.
Alginates/therapeutic use ; Endoscopy, Gastrointestinal ; Esophageal pH Monitoring ; GABA-B Receptor Agonists/therapeutic use ; Gastroesophageal Reflux/*diagnosis/drug therapy/pathology ; Humans ; Metoclopramide/therapeutic use ; Proton Pump Inhibitors/therapeutic use

Thirty-two adult female ASA I patients (American Society of Anesthesiologists' grading) undergoing voluntary termination of pregnancy (VTP) under general anaesthesia were randomly divided into three groups. Patients received 0.6 mg/kg pentazocine intravenously five minutes prior to induction of anaesthesia along with either isotonic saline, or promethazine 0.5 mg/kg or metoclopramide 0.2 mg/kg. Anaesthesia was induced with intravenous thiopentone and maintained with nitrous oxide in oxygen and boluses of thiopentone. Vomiting and sedation were scored at the end of anaesthesia, one hour later and at the time of discharge. The mean vomiting score was comparable in the three groups. Though the mean dose of thiopentone used was significantly less in the promethazine group, the sedation scores and the duration of stay in the clinic were comparable in all the groups. It is concluded that promethazine and metoclopramide in the doses used are ineffective as antiemetic agents in outpatient gynaecological patients.
Abortion, Induced ; methods ; Adult ; Ambulatory Surgical Procedures ; methods ; Analysis of Variance ; Anesthesia, General ; adverse effects ; Chi-Square Distribution ; Dilatation and Curettage ; methods ; Female ; Humans ; Metoclopramide ; administration & dosage ; therapeutic use ; Pregnancy ; Promethazine ; administration & dosage ; therapeutic use ; Statistics, Nonparametric ; Vomiting ; etiology ; prevention & control

To determine the contribution of metoclopramide to the efficacy of ondansetron in control of cisplatin-induced emesis, ondansetron was compared with ondansetron plus metoclopramide for antiemetic efficacy in a randomized double-blind trial. Enrolled 66 patients were treated with cisplatin(60mg/m2) in combination with etoposide, flourouracil, or vinblastine, and randomized to receive either ondansetron alone or ondansetron plus metoclopramide. Sixty patients were evaluable. Complete or major control of acute emesis was achieved in 96.6% (29/30) of patients given ondansetron plus metoclopramide and in 80% (24/30) receiving ondansetron alone, with no statistical significance (P = 0.07). However, delayed emesis (days 2-6) was better controlled by combination therapy than by ondansetron alone with 22 of 30 (73.4%) and 11 of 30 (36.7%), respectively (P = 0.03). No major drug-related side effects were observed. These results suggest that ondansetron plus metoclopramide is superior to ondansetron alone in the control of cisplatin induced delayed emesis without significant side effects.
Adult ; Aged ; Cisplatin/*adverse effects ; Comparative Study ; Double-Blind Method ; Drug Therapy, Combination ; Eating/drug effects ; Female ; Human ; Male ; Metoclopramide/*administration & dosage/adverse effects ; Middle Age ; Nausea/*prevention & control ; Ondansetron/administration & dosage/adverse effects/*therapeutic use ; Vomiting/*prevention & control